Neues zur Diagnostik und Therapie von Gliomen

Die zunehmend molekular basierte Klassifikation der hirneigenen Tumoren verspricht eine verbesserte prognostische Einteilung und eröffnet Optionen für neue Behandlungsansätze und molekular stratifizierte Studien. Herausragende grundlagenwissenschaftliche Erkenntnisse in der Molekulargenetik, der Immunologie und nicht zuletzt hinsichtlich der Wachstumsmuster von Gliomen erlauben die Entwicklung innovativer Konzepte.

Schlüsselwörter

Gehirntumor - Hirntumor - Neurologie - Onkologie - Molekulargenetik

• Literatur

• 1 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica 2016; 131: 803-820
• 2 Capper D, Jones DTW, Sill M. et al. DNA methylation-based classification of central nervous system tumours. Nature 2018; 555(7697): 469-474
• 3 Osswald M, Jung E, Sahm F. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 2015; 528(7580): 93-98
• 4 Melin BS, Barnholtz-Sloan JS, Wrensch MR. et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 2017; 49: 789-794
• 5 Miller AM, Shah RH, Pentsova EI. et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 2019; 565(7741): 654-658
• 6 Ellingson BM, Bendszus M, Boxerman J. et al. Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015; 17: 1188-1198
• 7 Weller M, van den Bent M, Tonn JC. et al. for the European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18: e315-e329 doi:10.1016/S1470-2045(17)30194-8
• 8 Nayak L, DeAngelis LM, Brandes AA. et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 2017; 19: 625-635
• 9 Harrison RA, Wefel JS. Neurocognitive Function in Adult Cancer Patients. Neurol Clin 2018; 36: 653-674
• 10 Buckner JC, Shaw EG, Pugh SL. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016; 374: 1344-1355
• 11 Wick W, Roth P, Hartmann C. et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 2016; 18: 1529-1537
• 12 van den Bent MJ, Baumert B, Erridge SC. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 2017; 390: 1645-1653
• 13 Wick W, Meisner C, Hentschel B. et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81: 1515-1522
• 14 Cairncross G, Wang M, Shaw E. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-343
• 15 van den Bent MJ, Brandes AA, Taphoorn MJ. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350
• 16 Stupp R, Mason WP, van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
• 17 Perry JR, Laperierre N, OʼCallaghan CJ. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017; 376: 1027-1037
• 18 Gramatzki D, Kickingereder P, Hentschel B. et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 2017; 88: 1422-1430
• 19 Malmstrom A, Gronberg BH, Marosi C. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926
• 20 Wick W, Platten M, Meisner C. et al. for the Neurooncology Working Group (NOA) of the German Cancer Society. Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 2012; 13: 707-715
• 21 Stupp R, Taillibert S, Kanner A. et al. Effect of tumor-treating fields plus maintenance temozolomide vs. maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306-2316
• 22 Wick W. TTFields: where does all the skepticism come from?. Neuro-Oncology 2016; 18: 303-305
• 23 Weller M. Tumor-treating fields: time for demystification. Ann Oncol 2018; 29: 1628-1630
• 24 Ryu S, Buatti JM, Morris A. et al. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2014; 118: 489-499
• 25 Wick W, Fricke H, Junge K. et al. A phase II, randomised, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 2014; 20: 6304-6313
• 26 Ma J, Benitez JA, Li J. et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell 2019; 35: 504-518
• 27 Brandes AA, Finocchiaro G, Zagonel V. et al. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro Oncol 2016; 18: 1304-1312 doi:10.1093/neuonc/now035
• 28 Wick W, Gorlia T, Bendszus M. et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 2017; 377: 1954-1963
• 29 Weller M, Tabatabai G, Kästner B. et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res 2015; 21: 2057-2064
• 30 Byron SA, Tran NL, Halperin RF. et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res 2018; 24: 295-305 doi:10.1158/1078-0432.CCR-17-0963
• 31 Körber V, Yang J, Barah P. et al. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell 2019; 35: 692-704.e12 doi:10.1016/j.ccell.2019.02.007
• 32 Stupp R, Wong ET, Kanner AA. et al. NovoTTF-100A versus physicianʼs choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48: 2192-2202
• 33 Chinot OL, Wick W, Mason W. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-722
• 34 Gilbert MR, Dignam JJ, Armstrong TS. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708
• 35 Wick W, Gorlia T, Bendszus M. et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 2017; 377: 1954-1963
• 36 Herrlinger U, Tzaridis T, Mack F. et al. Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393: 678-688
• 37 Hilf N, Kuttruff-Coqui S, Frenzel K. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019; 565: 240-245
• 38 Reardon DA, Omuro A, Brandes AA. et al. Randomized Phase 3 Study evaluating the efficacy and safety of nivolumab vs. bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology 2017; 19: iii21 doi:10.1093/neuonc/nox036.071
• 39 Byron SA, Tran NL, Halperin RF. et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clin Cancer Res 2017; pii:clincanres.0963.2017